SK3 Group Inc. (OTC: SKTO), a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine, recently announced that the first bottles of its new medical cannabis product, T-Hydrocan™ RMC 40, will be available on Wednesday on Pharmajames.com and subsequently from collectives that carry the YAK Edibles line of medical cannabis products.

The T-Hydrocan™ Refined Mixed Cannabinoids (“RMC”) 40 tablets contain 40mg of fully activated THC along with the attendant cannabinoids found in the cannabis/hemp source material. The cannabis oils were fully refined using organic processing materials that have been approved for contact with food, yielding a translucent red or gold colored essential oil containing a high concentrate.

“We are pleased to get this product to market so quickly,” said Artemus Mayer, President of SK3 Group. “Licensing fees from this product will go straight to the company’s bottom line and will give patients an [affordable] high dosage capsule.”

T-Hydrocan™ RMC 40 is packaged eight tablets per bottle with a suggested retail price of $35.00 per bottle. The company’s next product, T-Hydrocan™ Whole Plant 25 tablets and capsules. The products are being developed by Berkeley Bio-Organic Research Laboratories, Inc. and are available through Pharmajames.com and select dispensaries throughout California to medical cannabis patients.

On April 4, 2014, SK3 Group and PharmaJames signed a definitive agreement to merge the two companies to create a single medical cannabis company that may qualify for a market up-listing to the AMEX or NASDAQ. A newly formed acquisition company will be created holding assets from both companies and shareholders of each company will receive shares in the newly formed entity.

Shares of SK3 Group Inc. fell more than 14% during Wednesday’s trading and are trading up more than 120% so far this year.

CannabisFN.com, owned by TDM Financial, is a leading provider of cannabis news and insights. CannabisFN.com may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. View Full Disclaimer